keyword
MENU ▼
Read by QxMD icon Read
search

renal clear cell cancer

keyword
https://www.readbyqxmd.com/read/29452772/metabolic-and-lipidomic-reprogramming-in-renal-cell-carcinoma-subtypes-reflects-regions-of-tumor-origin
#1
Elke Schaeffeler, Florian Büttner, Anna Reustle, Verena Klumpp, Stefan Winter, Steffen Rausch, Pascale Fisel, Jörg Hennenlotter, Stephan Kruck, Arnulf Stenzl, Judith Wahrheit, Denise Sonntag, Marcus Scharpf, Falko Fend, Abbas Agaimy, Arndt Hartmann, Jens Bedke, Matthias Schwab
BACKGROUND: Renal cell carcinoma (RCC) consists of prognostic distinct subtypes derived from different cells of origin (eg, clear cell RCC [ccRCC], papillary RCC [papRCC], and chromophobe RCC [chRCC]). ccRCC is characterized by lipid accumulation and metabolic alterations, whereas data on metabolic alterations in non-ccRCC are limited. OBJECTIVE: We assessed metabolic alterations and the lipid composition of RCC subtypes and ccRCC-derived metastases. Moreover, we elucidated the potential of metabolites/lipids for subtype classification and identification of therapeutic targets...
February 13, 2018: European Urology Focus
https://www.readbyqxmd.com/read/29450259/hand-assisted-laparoscopic-partial-nephrectomy-for-large-renal-carcinoma-with-succinate-dehydrogenase-deficiency
#2
Ann Buhl Bersang, Sarah Bube, Mikkel Fode, Nessn H Azawi
Background: Germline mutations in succinate dehydrogenase (SDH) are associated with multifocal cancers: pituitary gland tumors, pheochromocytomas, paragangliomas, gastrointestinal stromal tumors, and renal-cell carcinomas (RCCs). SDH-deficient renal-cell carcinoma (SDH-RCC) was first identified in 2004 as an inherited kidney cancer with mutations in the SDH gene. SDH consists of A, B, C, and D units. Mutation in the SDHB gene is the most common mutation in SDH-deficient RCCs. Case Presentation: We report a case of a 51-year-old healthy man diagnosed with SDHB germline mutation and RCCs...
2018: Journal of Endourology Case Reports
https://www.readbyqxmd.com/read/29449729/parotid-metastasis-of-renal-cell-carcinoma-mimicking-primary-clear-cell-oncocytoma-report-of-a-case-and-brief-review-of-the-literature
#3
B J Rocca, A Gini, C Calandra, A Ginori, F Crivelli
Malignancies of the parotid gland are relatively uncommon, accounting for only 3-6% of all head and neck cancers. Most of them are primary neoplasms, metastases are uncommon. Renal cell carcinoma (RCC) represents 3% of adult malignancies, the clear cell type comprises up to 70% of all RCC. RCC has an unpredictable behavior and the unique potential to metastasize to nearly every organ in the body. Though not as frequent, metastatic RCC to the head and neck has been identified in the thyroid, salivary glands, skull base, sinuses, pharynx, tonsils, tongue, lip and skin...
December 2017: Pathologica
https://www.readbyqxmd.com/read/29440231/-ex-vivo-activity-of-cytotoxic-drugs-and-targeted-agents-in-small-intestinal-nets
#4
Kosmas Daskalakis, Olov Norlen, Andreas Karakatsanis, Per Hellman, Rolf Larsson, Peter Nygren, Peter Stalberg
Small intestinal endocrine tumours (SI-NETs) are generally considered resistant to systemic treatment. To date, predictive markers for drug activity are lacking. Tumour samples from 27 patients with SI-NETs were analyzed ex vivo for sensitivity to a panel of cytotoxic drugs and targeted agents using a short-term total cell kill assay. Samples of renal cancer, colorectal cancer (CRC), ovarian cancer, and chronic lymphocytic leukemia (CLL) were included for comparison. For the SI-NET subset, drug sensitivity was analyzed in relation to clinico-pathological variables and pre-treatment biomarkers...
February 12, 2018: Endocrine-related Cancer
https://www.readbyqxmd.com/read/29439857/axitinib-in-combination-with-pembrolizumab-in-patients-with-advanced-renal-cell-cancer-a-non-randomised-open-label-dose-finding-and-dose-expansion-phase-1b-trial
#5
Michael B Atkins, Elizabeth R Plimack, Igor Puzanov, Mayer N Fishman, David F McDermott, Daniel C Cho, Ulka Vaishampayan, Saby George, Thomas E Olencki, Jamal C Tarazi, Brad Rosbrook, Kathrine C Fernandez, Mariajose Lechuga, Toni K Choueiri
BACKGROUND: Previous studies combining PD-1 checkpoint inhibitors with tyrosine kinase inhibitors of the VEGF pathway have been characterised by excess toxicity, precluding further development. We hypothesised that axitinib, a more selective VEGF inhibitor than others previously tested, could be combined safely with pembrolizumab (anti-PD-1) and yield antitumour activity in patients with treatment-naive advanced renal cell carcinoma. METHODS: In this ongoing, open-label, phase 1b study, which was done at ten centres in the USA, we enrolled patients aged 18 years or older who had advanced renal cell carcinoma (predominantly clear cell subtype) with their primary tumour resected, and at least one measureable lesion, Eastern Cooperative Oncology Group performance status 0-1, controlled hypertension, and no previous systemic therapy for renal cell carcinoma...
February 9, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/29435287/secondary-tumours-of-the-ampulla-of-vater-case-report-and-review-of-the-literature
#6
Francesca Sarocchi, Magdalena M Gilg, Florian Schreiber, Cord Langner
Secondary tumours of the ampulla of Vater are rare. Underlying primary tumours, clinical presentation, macroscopic appearance, treatment strategies and outcome of secondary ampullary lesions have not been systematically analysed. The present case study reported a 57-year old patient with an ampullary metastasis from renal cancer and a literature review was performed in which a further 32 patients were included. The most common responsible primary tumours were malignant melanoma and renal clear cell carcinoma, followed by breast cancer...
February 2018: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/29435132/suppression-of-homology-dependent-dna-double-strand-break-repair-induces-parp-inhibitor-sensitivity-in-vhl-deficient-human-renal-cell-carcinoma
#7
Susan E Scanlon, Denise C Hegan, Parker L Sulkowski, Peter M Glazer
The von Hippel-Lindau ( VHL ) tumor suppressor gene is inactivated in the vast majority of human clear cell renal carcinomas. The pathogenesis of VHL loss is currently best understood to occur through stabilization of the hypoxia-inducible factors, activation of hypoxia-induced signaling pathways, and transcriptional reprogramming towards a pro-angiogenic and pro-growth state. However, hypoxia also drives other pro-tumorigenic processes, including the development of genomic instability via down-regulation of DNA repair gene expression...
January 12, 2018: Oncotarget
https://www.readbyqxmd.com/read/29434939/identification-of-metabolism-associated-genes-and-pathways-involved-in-different-stages-of-clear-cell-renal-cell-carcinoma
#8
Hui-Juan Li, Wen-Xing Li, Shao-Xing Dai, Yi-Cheng Guo, Jun-Juan Zheng, Jia-Qian Liu, Qian Wang, Bi-Wen Chen, Gong-Hua Li, Jing-Fei Huang
The lack of early diagnostic markers and novel therapeutic targets for clear cell renal cell carcinoma (ccRCC) negatively affects patient prognosis. Cancer metabolism is an attractive area for the understanding of the molecular mechanism of carcinogenesis. The present study attempted to identify metabolic changes from the view of the expression of metabolism-associated genes between control samples and those of ccRCC at different disease stages. Data concerning ccRCC gene expression obtained by RNA-sequencing was obtained from The Cancer Genome Atlas and data on metabolism-associated genes were extracted using the Recon2 model...
February 2018: Oncology Letters
https://www.readbyqxmd.com/read/29433988/effectiveness-and-harms-of-using-kidneys-with-small-renal-tumors-from-deceased-or-living-donors-as-a-source-of-renal-transplantation-a-systematic-review
#9
REVIEW
Vital Hevia, Rhana Hassan Zakri, Claire Fraser Taylor, Harman Maxim Bruins, Romain Boissier, Enrique Lledo, Heinz Regele, Klemens Budde, Arnaldo Figueiredo, Alberto Breda, Cathy Yuhong Yuan, Jonathon Olsburgh
CONTEXT: Kidney transplantation is the best treatment for patients with end-stage renal disease. Incidence of small renal masses (SRMs), which most frequently are renal cell carcinomas (RCCs), is highest in patients aged >60 yr. The increasing age of donors can lead to the diagnosis of a higher number of SRMs when assessing the patient for transplantation, and so can theoretically decrease the number of kidneys suitable for transplantation. Aiming to increase the pool of kidneys suitable for transplantation, a number of studies have reported their experience using kidneys with SRMs for transplantation...
February 9, 2018: European Urology Focus
https://www.readbyqxmd.com/read/29426696/prognostic-impact-of-concomitant-loss-of-pbrm1-and-bap1-protein-expression-in-early-stages-of-clear-cell-renal-cell-carcinoma
#10
Walter Henriques da Costa, Isabela Werneck da Cunha, Aline Fusco Fares, Stephania M Bezerra, Luciana Shultz, Diego Abreu Clavijo, Deusdedit Vieira da Silva, George Jabboure Netto, Gustavo Cardoso Guimaraes, Stenio de Cassio Zequi
PURPOSE: To evaluate the prognostic impact of immunohistochemical expression of BAP1 and PBRM1 in patients with early stage (pT1-pT2N0M0) clear cell renal cell carcinoma (ccRCC). PATIENTS AND METHODS: A total of 441 consecutive patients treated surgically for stages I and II (TNM-AJCC 2010) ccRCC between 1990 and 2016 were selected. All cases were reviewed for uniform reclassification and the most representative tumor areas were selected for the construction of a tissue microarray...
February 6, 2018: Urologic Oncology
https://www.readbyqxmd.com/read/29422388/acetazolamide-based-18f-pet-tracer-in-vivo-validation-of-carbonic-anhydrase-ix-as-a-sole-target-for-imaging-of-ca-ix-expressing-hypoxic-solid-tumors
#11
Kunal N More, Jun Young Lee, Dong-Yeon Kim, Nam-Chul Cho, Ayoung Pyo, Misun Yun, Hyeon Sik Kim, Hangun Kim, Kwangseok Ko, Jeong-Hoon Park, Dong-Jo Chang
Carbonic anhydrase IX is overexpressed in many solid tumors including hypoxic tumors and is a potential target for cancer therapy and diagnosis. Reported imaging agents targeting CA-IX are successful mostly in clear cell renal carcinoma as SKRC-52 and no candidate was approved yet in clinical trials for imaging of CA-IX. To validate CA-IX as a valid target for imaging of hypoxic tumor, we designed and synthesized novel [18F]-PET tracer (1) based on acetazolamide which is one of the well-known CA-IX inhibitors and performed imaging study in CA-IX expressing hypoxic tumor model as 4T1 and HT-29 in vivo models other than SKRC-52...
February 1, 2018: Bioorganic & Medicinal Chemistry Letters
https://www.readbyqxmd.com/read/29416926/arrdc1-and-arrdc3-act-as-tumor-suppressors-in-renal-cell-carcinoma-by-facilitating-yap1-degradation
#12
Jiantao Xiao, Qing Shi, Weiguo Li, Xingyu Mu, Jintao Peng, Mingzi Li, Mulin Chen, Huabing Huang, Chenji Wang, Kun Gao, Jie Fan
The α-arrestins domain-containing 1 and 3 (ARRDC1 and ARRDC3) are two members of the α-arrestins family. Yes-associated protein 1 (YAP1) is a key downstream transcription co-activator of the Hippo pathway essential for cancer initiation, progression, or metastasis in clear cell renal cell carcinoma (ccRCC). The aim of this work was to elucidate the role of the α-arrestins in ccRCC tumorigenesis by identifying molecular interacting factors and exploring potential mechanisms. In this study, we identified YAP1 as a novel ARRDC3 interacting protein in RCC cells through tandem affinity purification and mass spectrometry...
2018: American Journal of Cancer Research
https://www.readbyqxmd.com/read/29416602/the-prognostic-significance-of-nuclear-expression-of-phf2-and-c-ebp%C3%AE-in-clear-cell-renal-cell-carcinoma-with-consideration-of-adipogenic-metabolic-evolution
#13
Jeong Hwan Park, Minsun Jung, Kyung Chul Moon
Clear cell renal cell carcinoma (ccRCC) is the most common subtype of renal cell carcinoma (RCC), and it has an unfavourable prognosis compared to other RCCs. Plant homeodomain finger 2 (PHF2) and CCATT/enhancer binding protein α (C/EBPα) play a role in the epigenetic regulation of adipogenesis, and their tumour suppressive functions have been elucidated. This study aimed to assess the nuclear expression of PHF2 and C/EBPα in ccRCC and to evaluate their role in pathogenesis and prognosis. The nuclear expression of PHF2 and C/EBPα was evaluated in 344 cases of ccRCC by immunohistochemistry, and adipogenesis was assessed based on cytoplasmic features...
January 2, 2018: Oncotarget
https://www.readbyqxmd.com/read/29416277/epidemiology-profile-of-renal-cell-carcinoma-a-10-year-patients-experience-at-king-abdulaziz-medical-city-national-guard-health-affairs-saudi-arabia
#14
Sarah Z Mahasin, Nourah Aloudah, Khaled Al-Surimi, Sultan S Alkhateeb
Purpose: The purpose of this study is to describe the epidemiological profile, histopathological features, and outcomes of patients diagnosed with renal cell carcinoma (RCC) in a tertiary referral center over 10 years. Methodology: This is a retrospective cohort of 219 Saudi patients diagnosed with RCC between June 2003 and May 2013. The variables collected included the sociodemographic details and clinical presentation. The histopathological features investigated include the tumors histological subtype, pathologic staging tumor, node, and metastasis descriptors, and lymph-vascular invasion...
January 2018: Urology Annals
https://www.readbyqxmd.com/read/29413689/germline-bap1-positive-patients-the-dilemmas-of-cancer-surveillance-and-a-proposed-interdisciplinary-consensus-monitoring-strategy
#15
Phoebe Star, Annabel Goodwin, Rony Kapoor, R Max Conway, Georgina V Long, Richard A Scolyer, Pascale Guitera
The germline BAP1 (BRCA1-associated protein-1) mutation and associated cancer pre-disposition syndrome was first described in 2011. Since then, physicians have considered this diagnosis for patients with a characteristic personal or family history of BAP1-associated tumours (mainly uveal and cutaneous melanoma, pleural/peritoneal mesothelioma, renal cell carcinoma and BAP1-deficient melanocytic lesions). However, a positive germline BAP1 mutation detection creates significant uncertainty in terms of appropriate cancer surveillance...
February 2, 2018: European Journal of Cancer
https://www.readbyqxmd.com/read/29410711/serum-mir-122-5p-and-mir-206-expression-non-invasive-prognostic-biomarkers-for-renal-cell-carcinoma
#16
Frauke G Heinemann, Yuri Tolkach, Mario Deng, Doris Schmidt, Sven Perner, Glen Kristiansen, Stefan C Müller, Jörg Ellinger
Background: MicroRNAs (miRNA) play a relevant role in carcinogenesis, cancer progression, invasion, and metastasis. Thus, they can serve as diagnostic/prognostic biomarkers. The knowledge on circulating miRNAs for clear cell renal cell carcinomas (ccRCC) is limited. Our study was designed to identify novel biomarkers for ccRCC patients. Results: The serum small RNA expression profile was determined in 18 ccRCC and 8 patients with benign renal tumors (BRT) using small RNA sequencing...
2018: Clinical Epigenetics
https://www.readbyqxmd.com/read/29410489/pattern-multiplicity-and-fumarate-hydratase-fh-s-2-succino-cysteine-2sc-staining-but-not-eosinophilic-nucleoli-with-perinucleolar-halos-differentiate-hereditary-leiomyomatosis-and-renal-cell-carcinoma-associated-renal-cell-carcinomas-from-kidney-tumors-without
#17
Marie Muller, Marine Guillaud-Bataille, Julia Salleron, Catherine Genestie, Sophie Deveaux, Abdelhamid Slama, Brigitte Bressac de Paillerets, Stéphane Richard, Patrick R Benusiglio, Sophie Ferlicot
Hereditary leiomyomatosis and renal cell carcinoma syndrome is characterized by an increased risk of agressive renal cell carcinoma, often of type 2 papillary histology, and is caused by FH germline mutations. A prominent eosinophilic macronucleolus with a perinucleolar clear halo is distinctive of hereditary leiomyomatosis and renal cell carcinoma syndrome-associated renal cell carcinoma according to the 2012 ISUP and 2016 WHO kidney tumor classification. From an immunohistochemistry perspective, tumors are often FH-negative and S-(2-succino)-cysteine (2SC) positive...
February 6, 2018: Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc
https://www.readbyqxmd.com/read/29410248/tfcp2-tfcp2l1-ubp1-transcription-factors-in-cancer
#18
Grzegorz Kotarba, Ewa Krzywinska, Anna I Grabowska, Agnieszka Taracha, Tomasz Wilanowski
The TFCP2/Grainyhead family of transcription factors is divided into two distinct subfamilies, one of which includes the Grainyhead-like 1-3 (GRHL1-3) proteins and the other consists of TFCP2 (synonyms: CP2, LSF, LBP-1c), TFCP2L1 (synonyms: CRTR-1, LBP-9) and UBP1 (synonyms: LBP-1a, NF2d9). Transcription factors from the TFCP2/TFCP2L1/UBP1 subfamily are involved in various aspects of cancer development. TFCP2 is a pro-oncogenic factor in hepatocellular carcinoma, pancreatic cancer and breast cancer, may be important in cervical carcinogenesis and in colorectal cancer...
February 7, 2018: Cancer Letters
https://www.readbyqxmd.com/read/29400663/clusterin-promotes-growth-and-invasion-of-clear-cell-renal-carcinoma-cell-by-upregulation-of-s100a4-expression
#19
Yuan Liu, Changping Men, Yingmin Xu, Kai Zhao, Lei Luo, Dahai Dong, Qinchao Yu
BACKGROUND AND OBJECTIVE: Clusterin promotes cell proliferation, motility and invasiveness in human renal cell carcinoma (RCC) cells but the underlying molecular mechanisms of this action are largely unknown. The aim of this study was to investigate the effects of clusterin on cancer cell growth, invasion and S100A4 expression and to determine the effects of clusterin on in vitro cell proliferation and migration and in vivo tumour growth in RCC cells. METHODS: We have established stable transfectants of highly invasive Caki-1 human RCC cells with expression of clusterin shRNA targeting clusterin (Caki-1/clusterin shRNA)...
January 19, 2018: Cancer Biomarkers: Section A of Disease Markers
https://www.readbyqxmd.com/read/29398265/predicting-oncologic-outcomes-in-renal-cell-carcinoma-after-surgery
#20
Bradley C Leibovich, Christine M Lohse, John C Cheville, Harras B Zaid, Stephen A Boorjian, Igor Frank, R Houston Thompson, William P Parker
BACKGROUND: Predicting oncologic outcomes is important for patient counseling, clinical trial design, and biomarker study testing. OBJECTIVE: To develop prognostic models for progression-free (PFS) and cancer-specific survival (CSS) in patients with clear cell renal cell carcinoma (ccRCC), papillary RCC (papRCC), and chromophobe RCC (chrRCC). DESIGN, SETTING, AND PARTICIPANTS: Retrospective cohort review of the Mayo Clinic Nephrectomy registry from 1980 to 2010, for patients with nonmetastatic ccRCC, papRCC, and chrRCC...
February 2, 2018: European Urology
keyword
keyword
77807
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"